Bisphosphonates; Bone Growth Drugs
Bisphosphonates are a type of drug that reduction in the risk of skeletal-related events (SREs) ranging from 8% to 41% compared with placebo.
41% for intravenous zoledronic acid, 23% for intravenous pamidronate
Based on current research, Xgeva (denosumab) is generally considered to be slightly better than intravenous zoledronic acid for treating cancer patients with bone metastases, as studies have shown Xgeva to be more effective in delaying the occurrence of skeletal-related events (SREs) like bone fractures, with similar overall survival rates between the two medications; however, it's important to consult with your doctor to determine the best option for your specific situation.
Malignant bone disease is common in patients with advanced solid tumors or multiple myeloma. Among patients with lung cancer, bladder cancer, or melanoma, approximately 40% develop bone metastases during the course of their disease [1]. Breast cancer (BC) and prostate cancer (PC) have an especially high potential for metastasis to bone, which occurs in approximately 75% of patients with stage IV disease
source: Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165ā176. doi: 10.1053/ctrv.2000.0210.
Point 1
short explanation

Point 2
short explanation
Point 3
short explanation

Who might benefit?
list of cancer types
explanation, if needed